CervoMed Inc. (CRVO)
13.51
3.53 (35.37%)
At close: Apr 02, 2025, 3:59 PM
13.22
-2.13%
Pre-market: Apr 03, 2025, 07:35 AM EDT
35.37% (1D)
| Bid | 12.99 |
| Market Cap | 117.57M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -2.02 |
| PE Ratio (ttm) | -6.69 |
| Forward PE | -1.22 |
| Analyst | Buy |
| Ask | 13.26 |
| Volume | 2,842,619 |
| Avg. Volume (20D) | 4,711,910 |
| Open | 10.10 |
| Previous Close | 9.98 |
| Day's Range | 9.99 - 14.00 |
| 52-Week Range | 1.80 - 25.92 |
| Beta | 1.83 |
About CRVO
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts....
Industry Biotechnology
Sector Healthcare
IPO Date May 23, 2008
Employees 15
Stock Exchange NASDAQ
Ticker Symbol CRVO
Website https://www.cervomed.com
Analyst Forecast
According to 8 analyst ratings, the average rating for CRVO stock is "Buy." The 12-month stock price forecast is $17.5, which is an increase of 29.53% from the latest price.
Stock ForecastsNext Earnings Release
CervoMed Inc. is scheduled to release its earnings on May 13, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
15 hours ago
+36.07%
CervoMed shares are trading higher after the compa...
Unlock content with
Pro Subscription
2 weeks ago
+3.2%
CervoMed shares are trading higher after Canaccord Genuity raised its price target on the stock from $12 to $21. Several firms also maintained Buy ratings on the stock.
